Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2

Eitemau Tebyg

• Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
  gan: Blackledge, G, et al.
  Cyhoeddwyd: (2004)
• A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
  gan: Höpfner, M, et al.
  Cyhoeddwyd: (2003)
• Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
  gan: Magné, N, et al.
  Cyhoeddwyd: (2002)
• Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
  gan: Okubo, S, et al.
  Cyhoeddwyd: (2004)
• Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
  gan: Giocanti, N, et al.
  Cyhoeddwyd: (2004)